Karuna Therapeutics Inc (NASDAQ:KRTX)
| 220.25 Delayed Data As of May 26 |  +0.44 / +0.20%Today’s Change | 93.47 Today|||52-Week Range 278.25 | +12.09% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $8.2B |
Company Description
Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company was founded by Andrew Miller, Eric Elenko, and Peter Jeffrey Conn in July 2009 and is headquartered in Boston, MA.
Contact Information
Karuna Therapeutics, Inc. 99 High Street Boston Massachusetts 02110 |
Employees
Shareholders
| Mutual fund holders | 58.93% |
| Other institutional | 36.12% |
| Individual stakeholders | 28.65% |
Top Executives
| William J. Meury | President, Chief Executive Officer & Director |
| Andrew Miller | Chief Operating Officer |
| Troy A. Ignelzi | Chief Financial Officer |
| Stephen Brannan | Chief Medical Officer |
| Steven Marc Paul | Director, Chief Scientific Officer, President-R&D |
